Revenue
2019
2020
2021
2022
2023
2024
2025
Caribou Biosciences, Inc. (CRBU)
Price$1.58Cached quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $11.2M | $10.0M | $34.5M | $13.9M | $9.6M | $12.4M | $5.8M |
| Research & development | $109.4M | $130.2M | $112.1M | $82.2M | $52.3M | $34.4M | $23.6M |
| Operating expenses | $159.5M | $176.6M | $150.5M | $120.3M | $76.6M | $48.5M | $40.1M |
| Operating income | −$148.3M | −$166.6M | −$116.1M | −$106.4M | −$67.0M | −$36.1M | −$34.3M |
| Operating margin | −1,329.37% | −1,667.16% | −336.63% | −768.17% | −697.84% | −292.24% | −592.69% |
| EBITDA | −$144.7M | −$162.7M | −$112.5M | −$104.8M | −$66.0M | −$35.2M | −$33.6M |
| EBITDA margin | −1,296.70% | −1,627.87% | −326.40% | −756.46% | −687.59% | −284.96% | −579.72% |
| Net income | −$148.1M | −$149.1M | −$102.1M | −$99.4M | −$66.9M | −$34.3M | −$23.4M |
| Net profit margin | −1,327.40% | −1,491.95% | −296.05% | −717.79% | −697.26% | −277.55% | −404.82% |
| Basic EPSper basic share | -$1.59 | -$1.65 | -$1.38 | -$1.64 | -$2.11 | -$4.01 | -$2.80 |
| Diluted EPSper diluted share | -$1.59 | -$1.65 | -$1.38 | -$1.64 | -$2.11 | -$4.01 | -$2.80 |
Owners
Reported shareholders
7.37%of listed shares
BlackRock, Inc.7.82M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BlackRock, Inc. | 7.37%7.82M shares |
Pfizer Inc | 4.43%4.69M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.97%4.21M shares |
Haurwitz Rachel E. | ≈3.60%3.82M shares |
MACKENZIE FINANCIAL CORP | 3.44%3.65M shares |
RENAISSANCE TECHNOLOGIES LLC | 2.62%2.77M shares |
Kynam Capital Management, LP | 2.36%2.5M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.24%2.37M shares |
ACADIAN ASSET MANAGEMENT LLC | 1.67%1.77M shares |
STATE STREET CORP | 1.54%1.63M shares |
BANK OF AMERICA CORP /DE/ | 1.33%1.41M shares |
TWO SIGMA INVESTMENTS, LP | 0.99%1.05M shares |
DIMENSIONAL FUND ADVISORS LP | 0.92%975.33K shares |
CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.73%775.81K shares |
Cambridge Investment Research Advisors, Inc. | 0.72%764.82K shares |
FMR LLC | 0.69%727.12K shares |
NORTHERN TRUST CORP | 0.67%712.97K shares |
MAVERICK CAPITAL LTD | 0.62%652.54K shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 0.58%613.8K shares |
VANGUARD FIDUCIARY TRUST CO | 0.57%606.39K shares |
Percentages use 106M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Feb 25, 2026Form 4 | Kelly Timothy PChief Technology Officer | SellCommon Stock | 6.2K | $1.93 | $12.0K | 73.1K |
| Feb 24, 2026Form 4 · 10b5-1 | Albertson Tina M.Chief Medical Officer | SellCommon Stock | 1.1K | $1.96 | $2.1K | 68.5K |
| Feb 24, 2026Form 4 | Khan Ruhi AhmadChief Business Officer | SellCommon Stock | 6.9K | $1.96 | $13.6K | 105.0K |
| Feb 24, 2026Form 4 | Kelly Timothy PChief Technology Officer | SellCommon Stock | 3.1K | $1.96 | $6.2K | 79.4K |
| Feb 24, 2026Form 4 | MCCLUNG BARBARA GChief Legal Officer | SellCommon Stock | 6.9K | $1.96 | $13.6K | 481.6K |